Show simple item record

dc.contributor.authorAtwine, D
dc.contributor.authorBonnet, M
dc.contributor.authorTaburet, AM
dc.date.accessioned2018-04-17T16:34:49Z
dc.date.available2018-04-17T16:34:49Z
dc.date.issued2018-04-06
dc.date.submitted2018-04-17
dc.identifier.citationPharmacokinetics of efavirenz in patients on antituberculosis treatment in high HIV and tuberculosis burden countries: a systematic review. 2018 Br J Clin Pharmacolen
dc.identifier.issn1365-2125
dc.identifier.pmid29624706
dc.identifier.doi10.1111/bcp.13600
dc.identifier.urihttp://hdl.handle.net/10144/619092
dc.description.abstractEfavirenz (EFV) and Rifampicin-Isoniazid (RH) are cornerstone drugs in HIV-tuberculosis (TB) co-infection treatment but with complex drug interactions, efficacy and safety challenges. We reviewed recent data on EFV and RH interaction in TB/HIV high-burden countries.
dc.language.isoenen
dc.publisherWiley-Blackwellen
dc.rightsArchived with thanks to British Journal of Clinical Pharmacologyen
dc.titlePharmacokinetics of efavirenz in patients on antituberculosis treatment in high HIV and tuberculosis burden countries: a systematic reviewen
dc.identifier.journalBritish Journal of Clinical Pharmacologyen
refterms.dateFOA2019-03-04T13:47:13Z
html.description.abstractEfavirenz (EFV) and Rifampicin-Isoniazid (RH) are cornerstone drugs in HIV-tuberculosis (TB) co-infection treatment but with complex drug interactions, efficacy and safety challenges. We reviewed recent data on EFV and RH interaction in TB/HIV high-burden countries.


Files in this item

Thumbnail
Name:
Atwine et al - 2018 - Pharmaco ...
Size:
1.604Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record